Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 5, 2025Open Access

Outcomes in patients with refractory/relapsed CNS lymphoma treated in complete remission：autologous transplantation vs. CAR-T therapy

View Full Paper
Ask AI
Bookmark
Share

Authors

FYFan YangRLRui LiuZFZhonghua Fu

Discussion

Loading...

Member takes

Overview

Observational study shows ASCT improves progression-free survival in relapsed CNS lymphoma patients, highlighting its efficacy over CAR-T therapy.

Key Points

  • Patients who received autologous transplantation while in complete remission had superior progression-free survival.
  • The 3-year progression-free survival for ASCT was 80%, compared to 64.8% for CAR-T therapy (P = 0.026).
  • A retrospective observational study analyzed patients treated with ASCT or CAR-T therapy in a hospital from 2021 to 2024.
  • These findings support autologous transplantation as potentially better than CAR-T therapy in this patient population.

Cite This Study

Yang et al. (2025) studied this question.

synapsesocial.com/papers/68c23887b210217d64777b2ahttps://doi.org/10.21203/rs.3.rs-7350145/v1
View Full Paper
Ask AI
Bookmark
Share